Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04825990
Title Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer (POINT)
Acronym POINT
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Gruppo Oncologico del Nord-Ovest
Indications
Therapies
Age Groups: senior | adult
Covered Countries ITA


No variant requirements are available.